Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

by Douoguih, Macaya , Goepfert, Paul A , Treanor, John , Van Hoof, Johan , Shukarev, Georgi , Robb, Merlin L , Sadoff, Jerald , Stoddard, Jeffrey , Le Gars, Mathieu , Neuzil, Kathleen M , Schuitemaker, Hanneke , Scheper, Gert , Offergeld, Kim , Barouch, Dan H , Hardt, Karin , Cauwenberghs, Nancy , Tanner, Tamzin , Truyers, Carla , Corey, Lawrence , Struyf, Frank , Vandebosch, An , Fennema, Hein , Ryser, Martin F , Cárdenas, Vicky , Gray, Glenda , Grinsztejn, Beatriz , Spiessens, Bart , Taylor, Kimberly L , Ruiz-Guiñazú, Javier , Marovich, Mary A

in Ad26COVS1 / Adolescent / Adult / Adverse events / Age / Aged / Asymptomatic Diseases - epidemiology / Coronaviruses / COVID-19 / COVID-19 - epidemiology / COVID-19 - mortality / COVID-19 - prevention & control / COVID-19 vaccines / COVID-19 Vaccines - administration & dosage / COVID-19 Vaccines - adverse effects / COVID-19 Vaccines - immunology / Disease transmission / Double-Blind Method / FDA approval / Female / Hospitalization - statistics & numerical data / Humans / Hypotheses / Immunogenicity, Vaccine / Incidence / Infections / Male / Middle Aged / Original / Pandemics / Patient Acuity / Placebos / Population / Proportional Hazards Models / Protein structure / Protocol / R&D / Research & development / Safety / Severe acute respiratory syndrome coronavirus 2 / Spike protein / Vaccine efficacy / Vaccines / Young Adult

2021

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

2021

Confirm

Do you wish to request the book?

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

2021

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Douoguih, Macaya,

Goepfert, Paul A,

Treanor, John,

Van Hoof, Johan,

Shukarev, Georgi,

Robb, Merlin L,

Sadoff, Jerald,

Stoddard, Jeffrey,

Le Gars, Mathieu,

Neuzil, Kathleen M,

Schuitemaker, Hanneke,

Scheper, Gert,

Offergeld, Kim,

Barouch, Dan H,

Hardt, Karin,

Cauwenberghs, Nancy,

Tanner, Tamzin,

Truyers, Carla,

Corey, Lawrence,

Struyf, Frank,

Vandebosch, An,

Fennema, Hein,

Ryser, Martin F,

Cárdenas, Vicky,

Gray, Glenda,

Grinsztejn, Beatriz,

Spiessens, Bart,

Taylor, Kimberly L,

Ruiz-Guiñazú, Javier,

Marovich, Mary A

2021

Overview

Ad26.COV2.S vaccine is a replication-incompetent human adenovirus type 26 vector containing the gene sequence that produces SARS-CoV-2 spike protein in a prefusion-stabilized conformation. In a randomized trial involving nearly 40,000 persons, vaccine efficacy was 66% against moderate to severe–critical Covid-19 and 85% against severe–critical Covid-19. Efficacy against the variant first identified in South Africa was 64% against moderate disease and 82% against severe–critical disease.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Ad26COVS1

/ Adolescent

/ Adult

/ Adverse events

/ Age

/ Aged

/ Asymptomatic Diseases - epidemiology